Does an ongoing Pulmonary Embolism (PE) lower Protein C levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, an ongoing pulmonary embolism (PE) can lower protein C levels. During an acute PE, the body's coagulation system becomes activated, consuming clotting factors and natural anticoagulants like protein C 1. This consumption occurs because protein C is utilized in the body's attempt to break down the abnormal clots. Additionally, inflammatory responses triggered by the PE can affect liver function, potentially reducing protein C production since it's synthesized in the liver.

Key Considerations

  • The activation of the coagulation system and the consumption of protein C can lead to a temporary decrease in protein C levels during an active PE.
  • Inflammatory responses triggered by the PE can also affect liver function, potentially reducing protein C production.
  • Certain anticoagulants, particularly vitamin K antagonists like warfarin, can also artificially lower protein C levels, further complicating interpretation during active treatment for PE 1.

Clinical Implications

  • For accurate assessment of baseline protein C levels, it's recommended to wait until at least 2-3 months after the acute thrombotic event and completion of anticoagulation therapy.
  • The management of PE should follow the latest guidelines, which recommend initiation of anticoagulation without delay in patients with high or intermediate clinical probability of PE, while diagnostic workup is in progress 1.
  • The choice of anticoagulant should be based on the patient's clinical profile and the presence of any contraindications, with a preference for non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) in eligible patients 1.

From the Research

Ongoing Pulmonary Embolism and Protein C Levels

  • There is no direct evidence in the provided studies to suggest that an ongoing pulmonary embolism (PE) lowers protein C levels 2, 3, 4, 5, 6.
  • The studies primarily focus on the treatment and management of PE, including the use of anticoagulants such as rivaroxaban and warfarin, and their efficacy and safety in real-world clinical practice 3, 4.
  • Protein C is not mentioned in any of the provided studies, and therefore, there is no information available to determine the effect of an ongoing PE on protein C levels.
  • Further research would be necessary to investigate the relationship between ongoing PE and protein C levels, as the current evidence does not provide any insight into this topic 2, 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pulmonary embolism: update on diagnosis and management.

The Medical journal of Australia, 2019

Research

Management of Acute Pulmonary Embolism.

Current cardiovascular risk reports, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.